<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574168</url>
  </required_header>
  <id_info>
    <org_study_id>BT-ALL-001-v2</org_study_id>
    <secondary_id>ChiCTR1800016541</secondary_id>
    <nct_id>NCT03574168</nct_id>
  </id_info>
  <brief_title>CD19-CAR-T Cells in Patients With R/R B-ALL</brief_title>
  <official_title>Phase I Study of the Safety and Efficacy of CD19-CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioceltech Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioceltech Therapeutics, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-lable phase 1 study to determine the safety and&#xD;
      efficacy of autologous or donor-derived allogeneic T cells expressing CD19 chimeric antigen&#xD;
      receptors (referred to as &quot;CD19-CAR-T cells&quot;) in patients with relapsed or refractory acute&#xD;
      B-cell lymphoblastic leukemia (R/R B-ALL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To investigate the safety and efficacy of autologous or HLA-haploidentical Allo-CD19-CAR-T&#xD;
      cells in the treatment of patients with relapsed or refractory acute B-cell lymphoblastic&#xD;
      leukemia.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      To Assess the patient's quality of life after receiving the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">July 20, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate, ORR</measure>
    <time_frame>Up to Day90 after the CD19-CAR-T cell infusion</time_frame>
    <description>The percentage of participants who achieved complete remission (CR) over all participants (CRR).&#xD;
The percentage of participants who achieved partial remission (PR) over all participants (PRR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amount of CAR-T cells remaining in vivo</measure>
    <time_frame>2 years after cell infusion.</time_frame>
    <description>Measure and analyze monthly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lifetime of CAR-T cells remaining in vivo</measure>
    <time_frame>2 years after cell infusion.</time_frame>
    <description>Measure and analyze monthly</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CD19-CAR-T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-CAR-T Cells</intervention_name>
    <description>T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.</description>
    <arm_group_label>CD19-CAR-T Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Obtain Informed Consent Form (ICF) voluntarily signed by the patient;&#xD;
&#xD;
          2. Age 3-70 years old;&#xD;
&#xD;
          3. Primary resistant or relapsed B-cell line acute lymphoblastic leukemia;&#xD;
&#xD;
          4. B cells are positive for CD19 expression;&#xD;
&#xD;
          5. Peripheral blood tumor cell load &lt;50%; 6. KPS score &gt;50 points;&#xD;
&#xD;
        7. Normal liver and kidney function; 8. Normal heart function; 9. Good follow-up&#xD;
        compliance; 10. Women of childbearing age (15-49 years old) must have a pregnancy test&#xD;
        within 7 days before treatment and have a negative result; Men and women with fertility&#xD;
        should agree to use effective contraception to ensure that during the study period and&#xD;
        following 3 months after treatment the women will not get pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with non-B cell acute leukemia;&#xD;
&#xD;
          2. Organ failure: Heart: Grade III and IV Liver: Class C with Child-Turcotte liver&#xD;
             function classification Kidney: Renal failure and uremia Lung: severe respiratory&#xD;
             failure Brain: Disabilities&#xD;
&#xD;
          3. Active infection;&#xD;
&#xD;
          4. Human immunodeficiency virus (HIV) positive;&#xD;
&#xD;
          5. Acute and chronic graft-versus-host disease (GVHD)&gt; Level 1；&#xD;
&#xD;
          6. Pregnant or lactating women;&#xD;
&#xD;
          7. Patients do not agree to use effective contraception during the treatment period and&#xD;
             following 3 months;&#xD;
&#xD;
          8. Patients who participated in other clinical studies at the same time;&#xD;
&#xD;
          9. The researcher believes that there are other factors that are not suitable for&#xD;
             inclusion in or influence the subject's participation in or completion of the study;&#xD;
&#xD;
         10. Long-term use greater doses of hormones than physiological doses.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peihua Lu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongwei Xu, MD, Phd</last_name>
    <phone>+86 010-69739722</phone>
    <email>willyxu001@bioceltech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <zip>065000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, MD, PhD</last_name>
      <phone>18611636172</phone>
      <email>peihua_lu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

